Welcome!

News Feed Item

Pfenex Reports Second Quarter 2014 Results and Provides Business Update

SAN DIEGO, Aug. 29, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

"With the successful completion of our initial public offering, we have the capital to continue to advance our biosimilar product candidates, derived from our proprietary protein expression platform," stated Bertrand C. Liang, chief executive officer of Pfenex. "We expect to complete the phase 1b/2a trial for our lead product candidate, PF582, a biosimilar to Lucentis, by the end of 2014 and initiate the phase 3 trial in mid-2015." 

Business Updates

  • On July 29, 2014 we closed our initial public offering.  Including the underwriters exercise of their option to purchase additional shares, 9,429,084 shares of common stock were sold in the offering for a total capital raise of approximately $52.6 million after underwriter fees and discounts but before deducting offering expenses.
  • With the close of our initial public offering, Pfenex expanded the leadership team through the addition of two new board members, William R. Rohn and Philip R. Schneider. Mr. Rohn joined the board as chairman and brings extensive biotech industry experience having served in managerial roles at Biogen IDEC, IDEC Pharmaceuticals and Adria Laboratories. Mr. Schneider also joined the board with broad industry experience through previous management positions with IDEC Pharmaceuticals and Syntex Pharmaceuticals.

Financial Highlights for the three months ended June 30, 2014

  • Total revenue for the second quarter of 2014 was $3.3 million compared to $2.3 million in the second quarter of 2013.   The increase in revenue was due to an increase in activity related to our Px563L product candidate development under our government contracts, offset in part by a decrease in the protein production service work. 
  • Cost of revenue was $2.5 million in the second quarter of 2014 compared to $1.3 million in the second quarter of 2013.  The increase in cost of revenue was due primarily to the increased development costs for our proprietary novel vaccine programs which are funded by various government agencies.
  • Research and development expenses were $0.9 million for the second quarter of 2014 compared to $1.3 million in the second quarter of 2013.  The decrease in research and development expenses was due in part to an increase in development activity by our partner, Stelis, and resulting decrease in activity by Pfenex, of PF530, as well as manufacturing activity and purchase of comparator material for our product candidate, PF582, phase 1b/2a trial in the year ago period.  We expect research and development expense to increase as we advance our lead candidates and pipeline products.
  • Selling, general and administrative expenses were $2.0 million in the second quarter of 2014 compared to $1.7 million in the second quarter of 2013.  The increase in selling, general and administrative expenses was due to an increase in audit and consulting fees.  We expect selling, general and administrative expenses to increase for activities associated with operating as a public company. 
  • Not including the proceeds from our initial public offering and the exercise of the underwriters' option to purchase additional shares, cash, cash equivalents and short-term investments, excluding restricted cash, was $3.9 million as of June 30, 2014, compared to $5.2 million as of December 31, 2013.  As of June 30, 2014 we had $3.8 million drawn under our $3.9 million revolving credit facility and $4.0 million of restricted cash as collateral for the credit facility.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Pfenex's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, Pfenex's expectations regarding the development pathway, timing and success of its clinical trials for PF582 and its other product candidates. The Company's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Pfenex's ability to successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Pfenex's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Pfenex's ability to manage operating expenses, Pfenex's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Pfenex's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in the final prospectus related to Pfenex's initial public offering filed with the Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as discussions of potential risks, uncertainties, and other important factors in Pfenex's subsequent filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Pfenex as of the date hereof, and Pfenex disclaims any obligation to update any forward-looking statements, except as required by law.

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology™ platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.  

Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.  For more information, including a copy of our Corporate Presentation dated August 2014, visit (http://pfenex.investorroom.com).

 

Pfenex, Inc.

Condensed Statement of Operations

(in thousands, except per share data)

(Unaudited)




Three Months Ended

June 30,


Six Months Ended

June 30, 



2014


2013


2014


2013










Revenue


$       3,266


$     2,309


$       5,824


$     5,694

Cost of revenue



2,544



1,306



4,452



3,335

Gross Profit


722


1,003


1,372


2,359

Operating expenses:









Selling, general and administrative


2,024


1,676


3,519


3,459

Research and development


860


1,272


1,538


2,052

Total operating expenses


2,884


2,948


5,057


5,511

Loss from operations


(2,162)


(1,945)


(3,685)


(3,152)

Other expense, net


(21)


(9)


(39)


(10)

       Net loss before income taxes


(2,183)


(1,954)


(3,724)


(3,162)

Income tax benefit (expense)


-


777


(1)


1,259

Net loss


$    (2,183)


$   (1,177)


$    (3,725)


$  (1,903)

Effective preferred stock dividends


$       (447)


$      (419)


$       (882)


$     (827)

Net loss attributable to common stockholders                  


$    (2,630)


$   (1,596)


$    (4,607)


$  (2,730)










Net loss per common share basic and diluted


$      (1.67)


$     (1.04)


$      (2.95)


$    (1.80)

Weighted-average common shares used to compute basic and diluted net loss per share


1,571


1,542


1,560


1,520
























 

 

Pfenex, Inc.

Balance Sheets

(In thousands, except share and par value amounts)

(Unaudited)




June 30, 2014


December 31, 2013

Assets





Current assets:





Cash and cash equivalents


$          3,941


$              3,954

Short-term investments


-


1,250

Accounts and unbilled receivables, net


1,355


3,461

Inventories finished goods


18


26

Income tax receivable


401


398

Deferred income taxes


3,481


3,481

Other current assets


1,519


284

Total current assets


10,715


12,854

Restricted cash


4,030


4,029

Property and equipment, net


2,102


2,329

Notes receivable from related parties


-


95

Other long term assets


36


36

Intangible assets, net


6,628


6,893

Goodwill


5,577


5,577

Total assets


$        29,088


$             31,813






Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)





Current liabilities:





Accounts payable


$          1,127


$               1,804

Accrued liabilities


4,570


2,953

Deferred revenue


997


1,253

Line of credit obligation


3,813


-

Total current liabilities


10,507


6,010

Deferred tax liability


3,481


3,481

Line of credit obligation


-


3,590

Other long-term liabilities


3


3

Total liabilities


13,991


13,084

Commitments and contingencies (Notes 9 and 10)





Redeemable convertible Series A-2 preferred stock, par value $0.001,





   5,000,000 and 4,978,662 shares authorized at June 30, 2014 and December 31, 2013, respectively; 3,556,186 shares issued and





   outstanding; $13,815,111 liquidation preference


49,400


49,200

Redeemable convertible Series A-1 preferred stock, par value $0.001,





   5,000,000 and 4,978,662 shares authorized at June 30, 2014 and December 31, 2013, respectively;, 4,978,661 shares issued and





   outstanding; $16,470,071 liquidation preference


64,540


63,980

Stockholders' equity (deficit):





Common stock, $.001 par value, 30,000,000 and 12,514,224 shares authorized at June 30, 2014 and December 31, 2013, respectively; 1,571,473 and 1,541,781 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively


4


2

Additional paid-in capital


-


-

Accumulated deficit


(98,847)


(94,453)

Total stockholders' equity (deficit)


(98,843)


(94,451)

Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)


$        29,088


$             31,813








Note: The Pfenex Condensed Statement of Operations and Balance Sheet for the period ended June 30, 2014 does not reflect the Pfenex initial public offering that closed on July 29, 2014. 

Pfenex logo

Logo - http://photos.prnewswire.com/prnh/20140715/127348

SOURCE Pfenex Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...